Business Context and Reporting Period
Company: Bluejay Diagnostics, Inc. (BJDX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Bluejay is a medical diagnostics company developing the Symphony platform, a rapid, near-patient testing system for critical care settings. The primary product candidate is the Symphony IL-6 test for sepsis monitoring. The company has not yet received FDA clearance and is currently redeveloping manufacturing processes for cartridges and conducting the SYMON-II pivotal clinical trial. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,597,632) | $(5,418,671) | N/A |
| Operating Expenses | $1,616,947 | $5,491,225 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,082,268 |
| Accumulated Deficit | N/A | N/A | $(40,087,455) |
| Current Liabilities | N/A | N/A | $1,148,913 |
| Long-Term Debt | N/A | N/A | $0 (Bridge notes repaid in 2024) |
| Net Cash Used in Operating Activities | N/A | $(4,598,705) | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, decreased to $5.49 million from $5.68 million in the prior year period. Research and Development (R&D) expenses decreased to $2.46 million from $2.92 million, while General and Administrative (G&A) expenses increased slightly to $3.03 million from $2.76 million.
- Net Loss: The net loss for the nine months ended September 30, 2025, was $5.42 million, a decrease from the $6.29 million loss in the same period in 2024. The prior year period included a significant non-cash "deemed dividend" of $13.2 million related to warrant modifications, which inflated the net loss applicable to common stockholders in 2024.
- Interest Expense: Interest expense dropped significantly to $652 for the nine months ended September 30, 2025, compared to $822,299 in the prior year, as the company repaid its bridge notes in late 2024.
- Cash Position: Cash and cash equivalents decreased from $4.30 million at December 31, 2024, to $3.08 million at September 30, 2025, reflecting continued negative operating cash flows.
Guidance, Outlook, Risks, and Unusual Items
- Capital Requirements: Management states the company expects to need to raise at least $20 million between the filing date and the end of fiscal year 2027 to fund operations, clinical trials, and FDA submission efforts.
- Going Concern: The filing raises substantial doubt about the company's ability to continue as a going concern. Management estimates current cash resources (including proceeds from an October 2025 private placement) will fund operations only through the third quarter of 2026.
- Regulatory Timeline: The company plans to begin testing samples from the SYMON-II clinical trial by the end of 2026, with a goal of submitting a 510(k) application to the FDA in 2027.
- Recent Financing (Subsequent Event): On October 9, 2025, the company completed a private placement raising approximately $4.5 million. This transaction included the issuance of common stock, prefunded warrants, and Series F warrants. It also included a registration rights agreement with potential liquidated damages if registration deadlines are missed.
- Manufacturing Risks: The company is reliant on a third-party contractor (Sanyoseiko) to redevelop cartridge manufacturing processes. Failure to meet performance requirements or secure the manufacturing site by October 2026 could result in the termination of the license agreement with Toray Industries.
- Warrant Overhang: The company has a significant number of outstanding warrants (including Class E, Class C, and Series F) which, if exercised, would represent a substantial portion of the outstanding common stock, potentially diluting existing shareholders.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.5 million raised in October 2025 to bridge the gap until the next anticipated funding round, given the Q3 2026 liquidity horizon.
- Manufacturing Milestones: Confirm progress on the cartridge manufacturing redevelopment with Sanyoseiko and the timeline for establishing the alternative manufacturing site by October 2026.
- Clinical Trial Enrollment: Monitor the enrollment status of the SYMON-II pivotal clinical trial, which is currently at approximately 50% of the targeted population.
- Registration Rights Compliance: Track the company's ability to file and have declared effective the resale registration statement for the October 2025 private placement to avoid liquidated damages.
- Dilution Impact: Assess the potential dilution from the large volume of outstanding warrants (over 8 million shares underlying various warrant classes) relative to the current share count of approximately 1.64 million.